

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hoshino, S., Sun, B., Konishi, M., Shimura, M., Segawa, T., Hagiwara, Y., Koyanagi, Y., Iwamoto, A., Mimaya, J., Terunuma, H., Kano, S., and Ishizaka, Y.	Vpr in plasma of HIV-1-positive patients is correlated with the HIV-1 RNA titers.	AIDS Research and Human Retroviruses	23	391-397	2007
Wichukchinda, N., Kitamura, Y., Rojanawiwat, A., Nakayama, E.E., Song, H., Pathipvanich, P., Auwanit, W., Sawanpanyalert, P., Iwamoto, A., Shioda, T., and Ariyoshi, K.	The polymorphisms in DC-SIGNR affect susceptibility to HIV-1 infection.	AIDS Research and Human Retroviruses	23	686-692	2007
Song, H., Nakayama, E.E., Likanonsakul, S., Wasi, C., Iwamoto, A., and Shioda, T.	A three-base-deletion polymorphism in the upstream non-coding region of human interleukin 7 (IL-7) gene could enhance levels of IL-7 expression.	International J. Immunogenetics	34	107-113	2007

Nakayama, E.E., Carpentier, W., Costagliola, D., Shioda, T., Iwamoto, A., Debre, P., Yoshimura, K., Autran, B., Matsushita, S., and Theodorou, I.	Wild type and H43Y variant of human TRIM5 $\alpha$ show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro.	International J. Immuno- genetics	59	511-515	2007
Liu, H., Nakayama, E.E., Theodorou, I., Nagai, Y., Likansakul, S., Wasi, C., Debre, P. Iwamoto, A., and Shioda, T.	Polymorphisms in CCR5 chemokine receptor gene in Japan.	International J. Immuno- genetics	34	325-335	2007
Tomonari, A., Tsukada, N., Takahashi, S., Ooi, J., Konuma, T., Kobayashi, T., Fukuno, K., Takasugi, K., Fujii, T., Endo, T., Iwamoto, A., Oyaizu, N., Tojo, A., Asano, S.	Early-onset pulmonary complication showing organizing pneumonia pattern following cord blood transplantation in adults.	Interntl. J. Hematol.	85	364-366	2007
Hosoya, N., Miura, T., Kawana- Tachikawa, A., Shioda, T., Odawara, T., Nakamura, T., Kitamura, Y., Kano, M., Kato, A., Hironaka, T., Hasegawa, M., Nagai, Y., and Iwamoto, A.	Comparison between Sendai virus and Adenovirus vectors in induction of HIV-1 genes into human dendritic cells.	J. Medical Virology	80	373-382	2008
Maeda, T., Oyaizu, N., Endo, T., Odawara, T., Nakamura, T., Iwamoto, A., Fujii, T.	Pneumocystis jiroveci pneumonia in an AIDS patient: Unusual manifestation of multiple nodules with multiloculated cavities.	European Journal of Radiology	In Press		

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Song, H., Nakayama, EE., Likansakul, S., Wasi, C., Iwamoto, A. and Shioda, T.	A three-base-deletion polymorphism in the upstream non-coding region of human interleukin 7 (IL-7) gene could enhance levels of IL-7 expression.	Int. J. Immunogene t.	34	107-13	2007
Wichukchinda, N., Rojanawiwat, A., Kitamura, Y., Nakayama, EE., Pathipvanich, P., Auwanit, W., Sawanpanyalert, P., Iwamoto, A., Shioda, T. and Ariyoshi, K.	The polymorphisms in <i>DC-SIGNR</i> affect the susceptibility to HIV-1 infection.	AIDS. Res. Hum. Retrovir.	23	686-92	2007
Lwembe, R., Ochieng, W., Panikulam, A., Mongoina, C., Palakudy, T., Koizumi, Y., Kageyama, S., Yamamoto, N., Shioda, T., Musoke, R., Owens, M., Songok, EM., Okoth, FA. And Ichimura, H.	ANTI-RETROVIRAL DRUG RESISTANCE-ASSOCIAT ED MUTATIONS AMONG NON-SUBTYPE B HIV-1-INFECTED KENYAN CHILDREN WITH TREATMENT FAILURE.	J. Med. Virol.	79	865-72	2007

Ohishi, M., Shioda, T. and Sakuragi, J.	Retro-transduction by virus pseudotyped with glycoprotein of vesicular stomatitis virus.	Virology.	362	131-8	2007
Koizumi, Y., Kageyama, S., Fujiyama, Y., Miyashita, M., Lwembe, R., Ogino, K., Shioda, T. and Ichimura, H.	RANTES -28G delays and DC-SIGN -139C enhances AIDS progression in HIV-1-infected Japanese hemophiliacs.	AIDS Res. Hum. Retrovir.	23	713-9	2007
Nakayama, EE., Carpentier, W., Costagliola, D., Shioda, T., Iwamoto, A., Debre, P., Yoshimura, K., Autran, B., Matsushita, S. and Theodorou, I.	Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro.	Immunogene tics.	59	511-5	2007
Song, H., Nakayama, EE., Yokoyama, M., Sato, H., Levy, JA. and Shioda, T.	A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas.	J. Virol.	81	7280-5	2007
Sakuragi, J., Sakuragi, S. and Shioda, T.	Minimal region sufficient for genome dimerization in the human immunodeficiency virus type 1 virion and its potential roles in the early stages of viral replication.	J. Virol.	81	7985-92	2007
Koh, Y., Matsumi, S., Das, D., Amano, M., Davis, DA., Li, J., Leschenko, S., Baldrige, A., Shioda, T., Yarchoan, R., Ghosh, AK. and Mitsuya, H.	Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.	J. Biol. Chem.	282	28709-20	2007

Liu, H., Nakayama, EE., Theodorou, I., Nagai, Y., Likanonsakul, S., Wasi, C., Debre, P., Iwamoto, A. and Shioda, T.	Polymorphisms in CCR5 chemokine receptor gene in Japan.	Int. J. Immunogenet.	34	325-335	2007
Louisirirotchanakul, S., Sutthent, R., Wasi, C., Chuenchitra, T., Nitayaphan, S., Brown, AE., Polonis, VR., Nakayama, EE., Shioda, T., Liu, H. and Takebe, Y.	Host Genetic Analysis of HIV-1 Subtype CRF01_AE(E)-Infected Thai Patients with Different Rates of Disease Progression.	AIDS Res. Hum. Retrovir.	23	1605-1607	2007
Sugimoto, C., Nakayama, EE., Shioda, T., Villinger, F., Ansari, AA., Yamamoto, N., Suzuki, Y., Nagai, Y. and Mori, K.	Impact of Glycosylation on Antigenicity of Simian Immunodeficiency Virus SIV239: Induction of Rapid V1/V2 Specific Non-neutralizing Antibody and Delayed Neutralizing Antibody Following Infection with an Attenuated Deglycosylated SIV239 Mutant.	J. Gen. Virol.	89	554-66	2008
Hosoya, N., Miura, T., Kawana-Tachikawa, A., Koibuchi, T., Shioda, T., Odawara, T., Nakamura, T., Kitamura, Y., Kano, M., Kato, A., Hasegawa, M., Nagai, Y. and Iwamoto, A.	Comparison between Sendai virus and Adenovirus vectors to transduce HIV-1 genes into human dendritic cells.	J. Med. Virol.	80	373-82	2008
Wichukchinda, N., Nakayama, EE., Rojanawiwat, A., Pathipvanich, P., Auwanit, W., Vongsheree, S., Ariyoshi, K., Sawanpanyalert, P. and Shioda, T.	Effects of <i>CCR2</i> and <i>CCR5</i> polymorphisms on HIV-1 infection in Thai females.	J. AIDS.	in press		

Kono, K., Song, H., Shingai, Y., Shioda, T. and Nakayama, EE.	Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5 $\alpha$ s against HIV-2 infection.	Virology	in press		
Sakuragi, J., Sakuragi, S., Ohishi, M. and Shioda, T.	A rapid recombination assay of HIV-1 using murine CD52 as a novel biomarker.	Microbes Infect.	in press		
Nakayama, EE., Shingai, Y., Kono, K. and Shioda, T.	TRIM5 $\alpha$ -independent anti-human immunodeficiency virus type 1 activity mediated by cyclophilin A in Old World monkey cells	Virology	in press		

## 別紙4

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版地	出版年	ページ
なし							

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, Matsushita S.	Impact of V2 mutations for escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary HIV-1 isolate.	J Virol.	81	3757-3768	2007
Nakayama EE, Carpentier W, Costagliola D, Shioda T, Iwamoto A, Debre P, Yoshimura K, Autran B, Matsushita S, Theodorou I	Wild type and H43Y variant of human TRIM5 $\alpha$ show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro.	Immunogenetics	59	511-515	2007
Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita M, Shirasaka T, Kimura S, Oka S.	Successful efavirenz dose reduction in HIV-1-infected individuals with cytochrome P450 2B6*6 and *26.	Clin Infec Dis.	45	1230-1237	2007
Ryo A, Tsurutani N, Ohba K, Kimura R, Komano J, Nishi M, Soeda H, Hattori S, Perrem K, Yamamoto M, Chiba J, Mimaya J, Yoshimura K, Matsushita S, Honda M, Yoshimura A, Sawasaki, T, Aoki, I, Morikawa Y, Yamamoto N.	SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag.	Proc Natl Acad Sci U S A	105	294-299	2008

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出版地	出版年	ページ

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Raphael Lwembe, Hiroshi Ichimura 他 1 2 名	Anti-retroviral drug resistance-associated mutations among non- subtype B HIV-1 infected Kenyan children with treatment failure.	J Med Virol	79(7)	865-872	2007
Yusuke Koizumi, Hiroshi Ichimura 他 6 名	<i>RANTES</i> -28 <i>G</i> delays and <i>DC-SIGN</i> -139 <i>C</i> enhances AIDS progression in HIV- 1-infected Japanese hemophiliacs.	AIDS Res Hum Retroviruses	23(5)	713-719	2007
Nicaise Ndembi, Hiroshi Ichimura 他 6 名	Molecular Characterization of HIV-1 and HIV-2 in Yaounde, Cameroon: Evidence of Major Drug Resistance Mutations in Newly Diagnosed non-B Infected Patients.	J Clin Microbiol	46(1)	177-184	2008



## Vpr in Plasma of HIV Type 1-Positive Patients Is Correlated with the HIV Type 1 RNA Titers

SHIGEKI HOSHINO,<sup>1,2</sup> BINLIAN SUN,<sup>1</sup> MITSURU KONISHI,<sup>3</sup> MARI SHIMURA,<sup>1</sup> TATSUYA SEGAWA,<sup>4</sup> YOSHIKI HAGIWARA,<sup>4</sup> YOSHIO KOYANAGI,<sup>5</sup> AIKICHI IWAMOTO,<sup>6</sup> JUN-ICHI MIMAYA,<sup>7</sup> HIROSHI TERUNUMA,<sup>8</sup> SHIGEYUKI KANO,<sup>1,2</sup> and YUKIHITO ISHIZAKA<sup>1</sup>

### ABSTRACT

Vpr, an accessory gene product of HIV-1, has been reported in the plasma of HIV-1-positive patients, and exogenous Vpr induces the reactivation of viral production from latently infected cells and the apoptosis of T cells *in vitro*. These observations imply that Vpr is important in AIDS development, but the clinical relevance of the findings cannot be evaluated fully because the actual plasma Vpr concentration in HIV-1-positive patients is unknown. Here we generated two monoclonal antibodies against different portions of Vpr and successfully identified Vpr as a 14-kDa protein in HIV-1-positive patients. Semiquantitative analysis using a recombinant Vpr revealed that the concentration of Vpr in patient plasma was ~0.7 nM (10 ng/ml). Cross-sectional analysis of 52 HIV-1-positive patients revealed that the presence of Vpr detected in 20 patients was positively correlated with HIV-1 RNA copy number ( $p < 0.03$ ), but not with the number of CD4<sup>+</sup> T cells. This is the first report demonstrating the actual amount of Vpr in HIV-1-positive patients, and the possible linkage of Vpr and viral titers indicates that it is important to continue to carry out the sequential analysis of Vpr, especially in clinical courses of HIV-1-positive patients. The threshold of viral titers, where Vpr appears in the patients' plasma, if present, contributes to better understanding the role of Vpr in AIDS pathogenesis.

THE ADOPTION OF ANTIRETROVIRAL THERAPY (ART) has improved the prognosis of HIV-1-positive patients.<sup>1</sup> However, the complete elimination of the virus from patients receiving ART is estimated to take more than 60 years.<sup>2</sup> One factor that may be responsible for this problem is that HIV-1 infects macrophages, latent viral reservoirs<sup>3</sup> from which recurrent viral production is induced by various factors.<sup>4</sup> Vpr, an accessory gene of HIV-1, encodes a virion-associated 14-kDa protein that may be critical for the primary infection of macrophages.<sup>5-7</sup> Vpr also induces the reactivation of viral reproduction from latently infected cells. The presence of Vpr in the sera of HIV-1-positive patients, along with the induction of viral reproduction by exogenous Vpr,<sup>8,9</sup> implies that Vpr is ac-

tively involved in AIDS development. However, it is necessary to determine the concentration of Vpr in patient plasma samples to correctly evaluate the clinical significance of data obtained from *in vitro* experiments. In the current study, we successfully detected Vpr in patients' samples.

The protocol of this study was approved by the ethics committees of the International Medical Centre of Japan, Nara Medical University, Shizuoka Children's Hospital, and five other hospitals in collaboration with Shizuoka Children's Hospital. Blood plasma samples and peripheral blood were obtained from patients who had given informed consent after the experiment was explained to them. Clinical data on 14 outpatients at Nara Medical University, who were enrolled in the initial study, are

<sup>1</sup>Research Institute, International Medical Center of Japan, Shinjuku-ku, Tokyo 162-8655, Japan.

<sup>2</sup>Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba 305-8577, Japan.

<sup>3</sup>Center for Infectious Diseases, Nara Medical University, Kashihara, Nara 634-8522, Japan.

<sup>4</sup>Immuno-Biological Laboratories, Co., Fujioka, Gunma 375-0005, Japan.

<sup>5</sup>Laboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Sakyou-ku, Kyoto 606-8507, Japan.

<sup>6</sup>Department of Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Minato-ku 108-8639, Tokyo, Japan.

<sup>7</sup>Department of Hematology and Oncology, Children's Hospital of Shizuoka Prefecture, Aoi-ku, Shizuoka 420-8660, Japan.

<sup>8</sup>Biotherapy Institute of Japan, Koutou-ku, Tokyo, 135-0051, Japan.

summarized in Table 1. For the second study, samples from an additional 38 patients were analyzed. The median numbers of HIV-1 RNA copies (32,289.3 copies/ml), CD4<sup>+</sup> T cells (449.4 copies/ml), and total white blood cells (5049.0 cells/ml) were determined in all 52 patients. Control healthy plasma samples were obtained from Teragenix Corporation (Kokusai Bio, Tokyo). A recombinant Vpr protein (rVpr) was first prepared as a fusion protein with glutathione *S*-transferase (GST) expressed by pGEX6-P-1, and purified according to the manufacturer's protocol (GE Healthcare Bio-Sciences, Piscataway, NJ). The purified rVpr appeared as a single band on Coomassie brilliant blue staining (supplementary information 1a: SI-1a). Two mouse monoclonal antibodies, 8D1 (IgG2a) and C217 (IgG2b), were generated by immunization with a full-length Vpr peptide, chemically synthesized based on the prototype NL4-3<sup>10</sup> (Osaka Peptide Institute, Osaka), and a synthetic 18-mer amino acid peptide encompassing its carboxy (C)-terminal region (Wako Pure Chemical Industries, Tokyo, Japan), respectively. An enzyme-linked immunosorbent assay (ELISA) was based on 8D1, as the primary antibody, and a purified rabbit IgG antibody, raised against the peptide of the C-terminal 18 amino acids of Vpr (IBL, Fujioka, Japan), as the second antibody. Although the Vpr-ELISA could clearly detect purified rVpr (SI-1b), we found that the system occasionally detected one or more cross-reacting peptide in healthy persons (data not shown). Therefore, we decided to carry out a semiquantitative analysis using immunoprecipitation-Western blotting (IP-WB) analysis, with rVpr quantified by ELISA as the standard. For the IP-WB analysis, 0.5 mg of C217 was bound to Protein G Sepharose (GE Healthcare Bio-Sciences). Each 200  $\mu$ l of plasma was first treated with DNase I and RNase A for 5 min,

and then incubated with 10  $\mu$ l of C217-coupled beads for 2 h at 4°C. After being washed in buffer with 0.05% Tween-20, the immunoprecipitate was subjected to Western blot analysis. For standard samples, different amounts of purified rVpr were added to 200  $\mu$ l of control plasma. No detergents were added when the samples were incubated with the primary antibody, so that the IP-WB would detect only soluble Vpr, and not Vpr in viral particles.<sup>10</sup> The detection limit of the system was about 1 ng/ml (0.07 nM) (SI-2a).

Representative results from the IP-WB analysis of 14 plasma samples are shown in Fig. 1a. A definite signal of the 14-kDa protein was observed in patients N-09, 11, and 13 (Fig. 1a). By contrast, no peptides around 14 kDa were detected in more than 60 specimens from healthy volunteers (Fig. 1b). Because the IP-WB could selectively detect the 14-kDa peptide in the culture supernatant of cells containing an expression plasmid encoding *vpr* (SI-2b), we concluded that the 14-kDa peptide detected by the IP-WB was Vpr. A comparison of the signal intensities of the detected bands and standard rVpr (Fig. 1a; 5, 2.5, and 1.25  $\mu$ g/ml signals, and N-11) indicated that the serum Vpr concentration was about 0.7 nM.

During the analysis, we did not detect the Vpr signal in one patient (N-10; Table 1) who had 11,000 copies/ml of HIV-1 RNA (Fig. 1a, lower panel). To evaluate whether our system failed to detect Vpr mutants differing from the prototype NL4-3 (GenBank accession number M19921), we amplified DNA fragments from peripheral blood mononuclear cells covering the entire *vpr* gene. Then we determined its nucleotide sequence (Fig. 2a, and primers in SI-3). The deduced amino acid sequences are also shown in Fig. 2b. Interestingly, the *vpr* gene from patient N-10 had a four-nucleotide (TTAA) insertion at

TABLE 1. CLINICAL DATA OF PATIENTS SUBJECTED TO ANALYSIS AND RESULTS OF THE IP-WB

Case number	Sex	Age	Causes of infection	Conditions	Treatment status <sup>a</sup>	Clinical data			HIV-1 RNA (copies/ml)	Vpr <sup>b</sup>
						White blood cells (/mm <sup>3</sup> )				
						Total number	Lymphocytes	CD4 <sup>+</sup> T cells		
N-01	M	39	HO <sup>c</sup>	AIDS <sup>d</sup>	2	8400	2612	771	<50	-
02	M	41	HO	AIDS	2	6800	2584	346	<50	-
03	M	59	HE <sup>c</sup>	AIDS	2	4700	2444	381	260	-
04	F	32	HE	AC <sup>d</sup>	3	6300	1890	302	4,400	-
05	M	38	HO	AIDS	2	8600	2417	585	<50	-
06	M	35	HO	AC	1	4900	1274	116	220,000	+++
07	M	45	BL <sup>c</sup>	AIDS	2	2600	546	38	73,000	++
08	M	58	HE	AIDS	2	6800	1632	366	<50	-
09	M	29	BL	AC	1	3000	1056	266	17,000	+
10	M	23	HO	AC	1	5200	1300	230	11,000	-
11	F	37	HE	AC	1	4600	1150	222	500,000	+++
12	F	40	HE	AC	1	6600	1584	598	98	-
13	M	42	BL	AIDS	2	3100	1054	110	70,000	++
14	M	23	HO	AC	1	5800	2656	553	71,000	++

<sup>a</sup>Group 1, no therapy; group 2, under medication; group 3, posttherapy.

<sup>b</sup>Based on results of the IP-WB, patients are divided into four groups; Vpr-negative (-) and Vpr-positive with less than 1 ng/ml (+), with 1-5 ng/ml (++), and with more than 5 ng/ml (+++).

<sup>c</sup>HO, homosexual; HE, heterosexual; BL, blood products.

<sup>d</sup>AIDS, acquired immunodeficiency syndrome; AC, asymptomatic carrier.

nucleotide 81, designated "clone 10," which generates a frameshift mutation within the inserted sequence (shown by the box in Fig. 2a). However, because this patient had no deletion in the 3' region of the *vpr* gene, it was possible to clone the gene. Repeated sequence analyses of several clones of the amplified *vpr* DNA indicated that clone 10 was the major *vpr* in this patient (Table 2). The negative results of the IP-WB analysis for patient N-10 were therefore due to truncation of the C-terminal region.

Additional sequence analysis revealed that "clone N (Nara)," which differs by four amino acids from the prototype NL4-3 (Fig. 2b), was frequently observed in the analyzed patients (patients N-04, 05, 08, 09, 11, and 12). Interestingly, although patient N-09 had clone N as a major variant—all seven clones sequenced from the PCR products were identified as clone N (see Table 2)—the IP-WB analysis (Fig. 1a, lower panel) detected a positive Vpr signal in patient N-09. This suggests that C217 antibody, which was used as the first antibody in immunoprecipitation, reacts with the protein encoded by clone N, even though its C-terminal region differs from the prototype NL4-3 clone by two amino acids (Fig. 2b).

Next, we examined the possible correlation of Vpr and clinical manifestations. An analysis of 14 patients suggested a positive link between Vpr and viral titers (data not shown). To examine this possibility, we analyzed an additional 38 stocked samples using IP-WB. We detected Vpr in 14 samples. A representative result of the second analysis is shown in Fig. 1c. Positive Vpr signals were detected in patients T-166, 167, and 175. Then we examined the relationship between Vpr and RNA copy number in total 52 samples. As shown in Fig. 3a, we found a positive correlation between the detection of Vpr and RNA copy number ( $p < 0.03$ ). In contrast, we did not detect a positive relationship between Vpr and the numbers of CD4<sup>+</sup> T cells or total white blood cells. The distribution of Vpr-positive patients based on the concentration of Vpr implied that the high amount of Vpr is observed in patients with high HIV-1 RNA copy numbers (Fig. 3b).

In the current work, we successfully identified Vpr in 20 samples from 52 HIV-1-positive patients. A comparison of the signals obtained with standard rVpr revealed that the Vpr concentration was ~0.7 nM. Levy *et al.*<sup>9</sup> suggested that Vpr is present in patient plasma, with rVpr activating viral reproduction when added to the culture medium of latently infected cells. In addition, Muthumani *et al.* proposed that exogenous rVpr has various activities, such as inducing T cell apoptosis,<sup>11</sup> inhibiting macrophage function,<sup>12</sup> and suppressing NF- $\kappa$ B signaling.<sup>13</sup> However, these experiments did not consider the actual amount of Vpr present in the plasma samples. Our result is the first demonstration of Vpr in HIV-1-positive patients, and provides a rationale for the dose of rVpr suitable for *in vitro* experiments.

We observed a positive correlation between the detection of Vpr and HIV-1 RNA copy number ( $p < 0.03$ ) (Fig. 3a). It has been reported that the exogenous Vpr induces viral production from latently infected cells, implying that Vpr is involved in viral reproduction *in vivo*. An important question still to be answered is how the Vpr titer changes in the context of viral replication during the clinical course of the disease. It is important to clarify whether Vpr functions as an initial trigger of viral expansion *in vivo*.


We did not detect a link between Vpr and the numbers of CD4<sup>+</sup> T cells. Recently, it was determined that WT-Vpr and its variant R77Q act differently in modifying the clinical features of HIV-1-positive patients. Based on several reports, it has been proposed that R77Q is a candidate marker for long-term nonprogression (LTNP),<sup>14-16</sup> although this is still controversial.<sup>17,18</sup> In this study, we observed that the main Vpr variants of patients N-04, 09, and 10 were R77Q or C-terminally truncated. However, we did not recognize these patients as candidates for LTNP (clinical observation by M. Konishi). The involvement of WT-Vpr and R77Q in patients is rationalized by *in vitro* experiments showing that rVpr induces the apoptosis of CD4<sup>+</sup> T cells,<sup>11,12,14,15</sup> whereas R77Q has less potent apoptosis activity than WT-Vpr.<sup>15</sup> It is important to note that the *in vitro* studies of the differential activities of exogenous WT-Vpr and R77Q used tremendous amounts of the proteins, and a difference in activity was observed only when 1.5–2.0  $\mu$ M of the peptides was used.<sup>15</sup> As shown here, the concentration of Vpr in patient plasma was a maximum of 1.0 nM, and it is crucial to compare the functional difference of these molecules at a concentration comparable to that observed *in vivo*. Careful studies are required to address this matter.

## SUPPLEMENTARY INFORMATION


**SI-1.** Purification of rVpr and measurement using ELISA. (a) Expression and purification profiles of rVpr. Vpr was expressed as a fusion protein with GST and purified in a glutathione column. Lane 1, marker; lane 2, initial lysate; lane 3, flow-through sample eluted from the glutathione column; lane 4, eluate from rVpr after treatment with precision protease; and lane 5, eluate from an affinity column containing a monoclonal antibody against Vpr (8D1). The arrowhead and arrow indicate the position of GST-Vpr and purified rVpr, respectively. Proteins were stained with Coomassie brilliant blue solution. (b) ELISA version-1 for measuring rVpr. Synthesized full-length Vpr was used to make a standard curve. To the Vpr-ELISA were added 10 ng/ml each of GAPDH, HIV-1 integrase, and SARS-CoV Spike protein, which were expressed as a (His)-tagged protein, and purified using Ni-beads. Note that none of the samples gave cross-signals with Vpr. The amount of rVpr was assessed using the absorbance at OD450 nm, as shown with the dotted line.

**SI-2.** Detection of Vpr by the IP-WB. (a) Sensitivity of the system. The IP-WB analysis was conducted using C217 for IP and 8D1 for WB. To determine the sensitivity of the system, 10, 5, 2.5, and 1.25 ng of purified rVpr were added to 200  $\mu$ l of plasma from a healthy human just before the IP-WB analysis. The signals obtained using IP-WB (upper panel) and the input rVpr (lower panel) detected by 8D1 are shown. (b) Detection of Vpr in a culture supernatant. Culture supernatants (sup.) of 293FS cells (Invitrogen) transfected with pcDNA3.1 (center lane, "Vec") or pcDNA3.1-*vpr* (right lane, "Vpr") were collected on day 6 after transfection, and the IP-WB analysis was carried out. The rVpr (400 pg/lane) was included in the same blot as a positive control of WB (left lane).

**a**



**b**



**FIG. 1.** Detection of Vpr in sera of HIV-1-positive patients. (a) Presence of the 14-kDa Vpr protein in HIV-1-positive patients. To semiquantify the Vpr concentration in patient samples, 5, 2.5, and 1.25 ng of standard rVpr (lanes 2–5), which had been measured using ELISA version-1 (see supplementary information 1b; SI-1b), were included. As a positive control for the WB analysis, 1 ng of rVpr (lane 1) was also included. Signals of HIV-1-positive plasma (lanes 7–10) and a molecular marker (lane 6) are shown. (b) Representative results of the IP-WB analysis of healthy volunteers. The IP-WB analysis was performed on more than 60 samples from healthy volunteers, and representative results from 14 cases (lanes 4–17) are shown. Note that no signals were detected around 14 kDa. The results for input rVpr (lane 1), no rVpr (lane 2), or 5 ng Vpr (lane 3) added to normal plasma are shown. IgG signals recovered after IP are also shown (lower panel). (c) Detection of the 14-kDa Vpr protein in HIV-1-positive patients in the second group. Also in this analysis, 5, 2.5, and 1.25 ng of standard rVpr (lanes 2–5) were included to assess the concentration of Vpr in patient plasma samples.




FIG. 1. (Continued).

**SI-3.** Cloning and sequence analysis of *vpr*. DNA covering *vpr* was amplified from the genomic DNA of peripheral blood cells using nested PCR. The primers used were Vpr1F (nt 4713-4733, 5'-GACCCTGACCTAGCAGACCA-3') and Vpr1R (nt 5298-5318, 5'-CAAACCTGGCAATGAAAGCA-3') for the first PCR. For the second PCR, Vpr2F (nt. 4854-

4875, 5'-CAGTACTTGGCACTAGCAGCA-3') and Vpr2R (nt 5243-5263, 5'-TAGGCTGACTTCCTGGATGC-3') were used (GenBank accession number M19921). The first and second rounds of PCR were performed for 30 cycles of 95°C for 30 sec, 62°C for 30 sec, and 72°C for 1 min and for 95°C for 30 sec, 64°C for 30 sec, and 72°C for 45 sec, re-


**a**

NL4-3	1	ATGGAACAAG	CCCCAGAAGA	CCAAGGGCCA	CAGAGGGAGC	CATACAATGA	ATGGACACTA
Clone-10	1	-----	-----	-----	-----	-----	-----
	61	GAGCTTTTAG	AGGAACTTAA	GAGTGA	AGCTGTTAGA	CATTTTCCTA	GGATATGGCT
	61	-----	-----	TTAA	-----	-----	-----
	117	CCATAACTTA	GGACAACATA	TCTATGAAAC	TTACGGGGAT	ACTTGGGCAG	GAGTGGGAAGC
	121	-----	-----	-----	-----	-----	-----
	177	CATAATAAGA	ATTCTGCAAC	AACTGCTGTT	TATCCATTTC	AGAATTGGGT	GTCGACATAG
	181	-----	-----	-----	-----	-----	-----
	237	CAGAATAGGC	GTTACTCGAC	AGAGGAGAGC	AAGAAATGGA	GCCAGTAGAT	CCTAG 291nt.
	241	-----	-----	-----	-----	-----	295nt.

**b**

NL4-3	MEQAPEDQGPQREPYNEWTLLELLELKSEAVRHFPPRIWLHNLGQHIYETYGDTWAGVEAIIRILQQLFIHFRIGCRHSRIGVTRQRRARNGASRS
Clone-10	.....N*
Clone-N	.....Q.....II.....

**FIG. 2.** Sequence analysis of *vprs* and the deduced amino acids of Vpr variants in HIV-1-positive patients. The *vpr* gene was amplified and analyzed, as described in SI-3. (a) Nucleotide sequence of clone 10. The nucleotide sequence was compared with that of the prototype NL4-3. Clone 10 has a four-base insertion at nucleotide 81, generating a stop codon within the insert (indicated by the box). Nucleotides that are the same as those in NL4-3 are marked with small bars. (b) Amino acid sequences of Vpr variants found in the patients. The amino acids deduced from the obtained sequences and the NL4-3 clone are shown. As described in SI-3a, clone 10 was recognized as a major variant in patient N-10, while clone N was the major variant in patients N-04 and 09.



**FIG. 3.** Correlation between Vpr detection and clinical data. The analyzed cases were divided into Vpr-positive and Vpr-negative groups, and the statistical analysis was done using Student's *t*-test. (a). The relationships with the HIV-1 RNA copy number. The bars indicate the mean numbers in each group. The difference for HIV-RNA copy number with Vpr was statistically significant ( $p < 0.03$ ). (b) Distribution of Vpr-positive patients according to the concentration of plasma Vpr. Based on the semi-quantitative analysis, patients were divided into four groups: Vpr-negative (-), Vpr-positive with less than 1 ng/ml (+), 1-5 ng/ml (++), and more than 5 ng/ml (+++). Each dot means a patient.

spectively. The PCR products were cloned into pZeroBlunt topo vector (Invitrogen, Carlsbad, CA). Several clones were sequenced for each PCR product.

SI-4. See Table 2.

**TABLE 2.** FREQUENCY OF *vpr* VARIANTS IN HIV-1 PATIENTS<sup>a</sup>

Cases	<i>vpr</i> variants		
	NL4-3	Clone N	Clone 10
N-03	7 <sup>b</sup>	—	9
N-04	—	14	—
N-05	2	2	3
N-09	—	7	—
N-10	—	—	5
N-12	4	4	—

<sup>a</sup>PCR products amplified from patient genomic DNA were subcloned into the vector, and several clones were sequenced. The numbers in the table indicate the frequency of clones encountered in the sequence analyses. All 5 clones derived from patient N-10 were clone 10. In patients N-04 and 09, clone N was identified as the major variant; all 14 clones for patient N-04 and all 7 clones for patient N-09 were clone N. Patients N-03 and N-05 each had 2 *vpr* variants.

<sup>b</sup>Number of analyzed clones.

**ACKNOWLEDGMENTS**

We thank the healthy volunteers and C. Nakai-Murakami for donating peripheral blood and providing technical assistance. We are grateful for samples of HIV-1-positive patients to Drs. C. Kobayashi (National Hospital Organization Chiba Medical Center), I. Sato (National Hospital Organization Sendai Medical Center), H. Hanafusa (Ogikubo Hospital), J. Matsuda (Teikyo University School of Medicine), M. Sakai (University of Occupational and Environmental Health), S. Ikeda (Sasebo Municipal Hospital), and T. Fujii (Hiroshima University School of Medicine). This work was supported by a Grant-in-Aid for Research on Health Sciences focusing on Drug Innovation from the Japan Health Sciences Foundation Research and Research on HIV/AIDS from the Ministry of Health, Labor and Welfare of Japan. Dr. Sun is a research resident supported by the Foundation for AIDS prevention.

**REFERENCES**

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, *et al.*: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1998;338:853-860.

2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, *et al.*: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science* 1997;278:1295-1300.
3. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS: Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. *Science* 1987; 238:800-802.
4. Koyanagi Y, O'Brien WA, Zhao JQ, Golde DW, Gasson JC, and Chen ISY: Cytokines alter production of HIV-1 from primary mononuclear phagocytes. *Science* 1988;241:1673-1675.
5. Heinzinger NK, Bukrinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, *et al.*: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. *Proc Natl Acad Sci USA* 1994;91:7311-7315.
6. Vodicka MA, Koepp DM, Silver PA, and Emerman M: HIV-1 vpr interacts with the nuclear transport pathway to promote macrophage infection. *Genes Dev* 1998;12:175-185.
7. Jenkins Y, McEntee M, Weis K, and Greene WC: Characterization of HIV-1 vpr nuclear import: Analysis of signals and pathways. *J Cell Biol* 1998;143:875-885.
8. Levy DN, Refaeli Y, MacGregor RR, and Weiner DB: Serum vpr regulates productive infection and latency of human immunodeficiency virus type 1. *Proc Natl Acad Sci USA* 1994;91:10873-10877.
9. Levy DN, Refaeli Y, and Weiner DB: Extracellular vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. *J Virol* 1995;69:1243-1252.
10. Marzio PD, Choe S, Ebright M, Knoblauch R, and Landau NR: Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 vpr. *J Virol* 1995;69:7909-7916.
11. Muthumani K, Hwang DS, Desai BM, Zhang D, Dayes N, Green DR, *et al.*: HIV-1 vpr induces apoptosis through caspase 9 in T cells and peripheral mononuclear blood cells. *J Biol Chem* 2002; 277:37820-37831.
12. Muthumani K, Hwang DS, Choo AY, Mayilvahanan S, Dayes NS, Thieu KP, *et al.*: HIV-1 vpr inhibits the maturation and activation of macrophages and dendritic cells *in vitro*. *Int Immunol* 2004; 17:103-116.
13. Muthumani K, Choo AY, Zong W-X, Madesh M, Hwang DS, Premkumar A, *et al.*: The HIV-1 vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. *Nat Cell Biol* 2006;8:170-179.
14. Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, Yao X-J, *et al.*: Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. *J Clin Invest* 2003; 111:1547-1554.
15. Rodes B, Toro C, Paxinos E, Poveda E, Martinez-Padial M, Benito JM, *et al.*: Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. *AIDS* 2004;18:1109-1116.
16. Mologni D, Citterio P, Menzaghi B, Zanone PB, Riva C, Broggin V, *et al.*: Vpr and HIV-1 disease progression: R77Q mutation is associated with long term control of HIV-1 infection in different groups of patients. *AIDS* 2006;20:567-574.
17. Cavert W, Webb CH, Balfour HH Jr: Alterations in the C-terminal region of HIV-1 accessory gene vpr do not confer clinical advantage to subjects receiving nucleoside antiretroviral therapy. *J Infect Dis* 2004;20:2181-2184.
18. Chui C, Cheung PK, Brumme CJ, Mo T, Brumme ZL, Montaner JSG, *et al.*: HIV-1 VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. *AIDS Res Hum Retrovir* 2006;22:615-618.

Address reprint requests to:

Yukihito Ishizaka

Research Institute

International Medical Center of Japan

1-21-1 Toyama

Shinjuku-ku

Tokyo 162-8655, Japan

E-mail: zakay@ri.imcj.go.jp

## The Polymorphisms in *DC-SIGNR* Affect Susceptibility to HIV Type 1 Infection

NUANJUN WICHUKCHINDA,<sup>1,2</sup> YOSHIHIRO KITAMURA,<sup>3</sup> ARCHAWIN ROJANAWIWAT,<sup>1</sup>  
EMI E. NAKAYAMA,<sup>2</sup> HAIHAN SONG,<sup>2</sup> PANITA PATHIPVANICH,<sup>4</sup> WATTANA AUWANIT,<sup>1</sup>  
PATHOM SAWANPANYALERT,<sup>1</sup> AIKICHI IWAMOTO,<sup>3</sup> TATSUO SHIODA,<sup>2</sup> and KOYA ARIYOSHI<sup>5</sup>

### ABSTRACT

Dendritic cell-specific intercellular adhesion molecule-3 (ICAM-3) grabbing nonintegrin (*DC-SIGN*) and its homologue *DC-SIGNR* (*DC-SIGN* related) have been thought to play an important role in establishing HIV infection by enhancing *trans*-infection of CD4<sup>+</sup> T cells in the regional lymph nodes. To identify polymorphisms associated with HIV-exposed seronegative (ESN) individuals in Thais, genomic DNA from 102 HIV-seronegative individuals of HIV-seropositive spouses, 305 HIV-seropositive individuals, and 290 HIV-seronegative blood donors was genotyped for two single nucleotide polymorphisms (SNPs) in *DC-SIGN* promoter (–139A/G and –336A/G), a repeat number of 69 bp in Exon 4 of *DC-SIGN* and *DC-SIGNR*, and one SNP in Exon 5 of *DC-SIGNR* (rs2277998A/G). We found that the proportion of individuals possessing a heterozygous 7/5 and 9/5 repeat and A allele at rs2277998 of *DC-SIGNR* in HIV-seronegative individuals of HIV-seropositive spouses was significantly higher than HIV-seropositive individuals [ $p = 0.0373$ , OR (95% CI) = 0.57 (0.32,1.01);  $p = 0.0232$ , OR (95% CI) = 0.38 (0.15,0.98); and  $p = 0.0445$ , OR (95% CI) = 0.61 (0.37,1.02), respectively]. Analysis after stratifying by gender showed that these associations were observed only in females but not in males. Moreover, HIV-seropositive females tend to have a homozygous 7/7 repeat more frequently than HIV-seronegative females with a marginal level of significance [ $p = 0.0556$ , OR (95% CI) = 1.79 (0.94,3.40)]. Haplotype analysis showed that the proportion of individuals possessing the 5A haplotype in HIV-seronegative females was significantly higher than HIV-seropositive females [ $p = 0.0133$ , OR = 0.50 (0.27,0.90)]. These associations suggest that *DC-SIGNR* may affect susceptibility to HIV infection by a mechanism that is different in females and males. Further studies are warranted to investigate the mechanisms of their function.

### INTRODUCTION

SOME INDIVIDUALS, SUCH AS HIV-SERONEGATIVE COMMERCIAL SEX WORKERS and HIV-seronegative spouses of HIV-seropositive individuals, have been sexually exposed to HIV repeatedly, yet remain negative for anti-HIV antibody.<sup>1,2</sup> These individuals are recognized as HIV-exposed but seronegative persons (ESN). Our study in Thailand has identified a number of married couples in whom the serostatus of HIV infection was discordant between spouses and in the majority of cases, this discordance could not be explained by their sexual behavior,

such as frequency of unprotected sexual contacts, or by viral load of their infected spouses (Rojanawiwat *et al.*, submitted). These observations made us speculate that these seronegative spouses were likely to have certain biological mechanisms that made them resistant to HIV infection.

A number of polymorphisms in host genes that encode products involved in HIV replication and/or immune regulation were reported to be associated with HIV infection and HIV disease progression.<sup>3</sup> Among these, only the homozygous *CCR5* 32-bp deletion (*CCR5*Δ32) was found to be consistently associated with resistance to HIV infection.<sup>4–6</sup> However, the *CCR5*Δ32 al-

<sup>1</sup>National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.

<sup>2</sup>Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.

<sup>3</sup>Institute of Medical Science, University of Tokyo, Tokyo, Japan.

<sup>4</sup>Day Care Center, Lampang Hospital, Lampang, Thailand.

<sup>5</sup>Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.



lele is very rare among Asians,<sup>6-9</sup> including Thais.<sup>10</sup> Thus other unidentified genes are likely to play a role in resistance to HIV infection among ESN in Thailand.

Dendritic cell-specific intercellular adhesion molecule-3 (ICAM-3) grabbing nonintegrin (*DC-SIGN*, also called CD209) is a receptor on dendritic cells (DCs) that binds to ICAM-3 expressed on T cells to facilitate the initial interaction between DCs and T cells. *DC-SIGN* has been considered important in HIV research because it acts as an intermediate receptor for binding to HIV-1 at mucosal sites and then enhancing *trans*-infection of CD4<sup>+</sup> T cells in regional lymph nodes.<sup>11</sup> A homologue of *DC-SIGN* called *DC-SIGNR* (*DC-SIGN* related or CD209L or L-SIGN; the official name is C-type lectin domain family 4, member M, CLEC4M) shares 77% amino acid identity and exhibits a similar capacity of binding to HIV-1.<sup>12,13</sup> *DC-SIGN* is expressed at high levels on DCs and some types of macrophages,<sup>14,15</sup> whereas *DC-SIGNR* is expressed on endothelial cells in liver and lymph nodes.<sup>12,13,16</sup> Recently, the presence of *DC-SIGNR* mRNA was demonstrated in the human vaginal and rectal mucosa by nested reverse transcriptase polymerase chain reaction (RT-PCR).<sup>17</sup> Because *DC-SIGN* and *DC-SIGNR* have an apparent role in DC-T cell interaction and HIV infection, the polymorphisms associated with these genes may have an impact on the transmission of HIV as shown in several studies.<sup>18-23</sup> The objective of this study is, therefore, to identify those reported polymorphisms in *DC-SIGN* and *DC-SIGNR* that are associated with ESN individuals in Thais. Having investigated polymorphisms of these two genes among Thai couples, we found that polymorphisms in the *DC-SIGNR* but not in the *DC-SIGN* were significantly associated with ESN females but not with ESN males.

## MATERIALS AND METHODS

### *Patients and samples*

From 6 July 2000 to 15 October 2002 we conducted the Lampang HIV couple study at the HIV clinic in the Day Care Center of the Lampang Hospital, which is a referral hospital located about 600 km to the north of Bangkok (Rojanawiwat *et al.*, submitted). For this study of genetic polymorphisms, we recruited 188 couples, including 70 HIV-serodiscordant couples with 43 HIV-seronegative females and 27 HIV-seronegative males, and 118 HIV-seroconcordant couples. All 144 HIV-seropositive females and 155/161 (96.3%) HIV-seropositive males were heterosexually infected. There were two males with a history of injecting drug use, one male with blood transfusion, two males with more than one possible risk factor, and one male with no information. In terms of age, viral load, CD4<sup>+</sup> cell count, and clinical symptoms of HIV-infected spouses, there was no significant difference between discordant couples and concordant couples in both females and males, except that the proportion of HIV-infected males with HIV-seronegative wives was higher than that of HIV-infected males with HIV-infected wives (Table 1).

To increase the number of HIV seronegative spouses of HIV-infected individuals, we also included two HIV-seronegative individuals (one male, one female) who did not bring their HIV-seropositive spouses and 30 HIV-seronegative widows whose

husband died of HIV/AIDS. These widows were included because they were significantly exposed to HIV: the median [interquartile range (IQR)] frequency of sexual contact was four (2, 6) times per month and 26/30 (86%) of them had never used a condom before they were aware of HIV. Furthermore, we believe that the level of HIV exposure was very high because their index case has already progressed and died: in 14/30 (46%) women, their husband died within 1 year of disclosure and in 21/30 women (70%) within 2 years of disclosure. There was one HIV-seropositive female who previously had an HIV-positive husband and remarried an HIV-negative husband after her first husband died. Therefore in total, 102 HIV-seronegative individuals (74 females and 28 males) at high risk for HIV infection and 305 HIV-seropositive individuals (144 females and 161 males) were enrolled.

The median age (IQR) of both HIV-seronegative and HIV-seropositive individuals was 32 (29, 36) years. Among 74 HIV-seronegative female spouses, one of them had known her HIV status before the marriage. In the other 73 females, the median (IQR) duration of marriage before they knew the HIV status of their husbands was estimated to be 5 (3, 8) years. The median (IQR) frequency of sexual contacts before the disclosure of the HIV status of their husband was five (3, 8) times per month. Of females, 64 (87.7%) reported that they had never used a condom during those sexual contacts and only four (5.5%) reported that they used a condom at every contact. Among 28 HIV-seronegative male spouses, nine of them had known the HIV status of their wives before the marriage. In the other 19 HIV-seronegative males, the median (IQR) duration of marriage before the disclosure of HIV status of their wife was estimated to be 1 (0, 2) year. The median (IQR) frequency of sexual contact before the disclosure of the HIV status of their wife was six (4, 24) times per month, and all of them reported that they had never used a condom during sexual contacts.

For a control HIV-seronegative group representing the Thai general population, 290 blood samples were collected from blood donors (171 males and 119 females) at the blood bank of the Lampang Hospital. All participants gave written informed consent. This study was approved by the Ethical Review Committee for Research in Human Subjects, Ministry of Public Health, Thailand in January 2000.

EDTA-treated blood samples were separated for plasma and buffy coat, then stored at -80°C until used. Genomic DNA was extracted and purified from the frozen buffy coat using a kit (QIAamp mini blood kit; QIAGEN GmbH, Hilden, Germany).

HIV-1 serology was screened by an ELISA kit (Enzygnost anti-HIV-1/2 plus; Dade Behring Marburg GmbH, Marburg, Germany). The positive samples were then confirmed by another ELISA kit (Genscreen HIV 1/2 Diagnostic Pasteur Ltd., France) and a gel particle agglutination test (Serodia HIV-1; Fujirebio Inc., Tokyo Japan).

### *Polymorphism genotyping*

*DC-SIGN* promoter: -139A/G (rs2287886) and -336A/G (rs4804803); *DC-SIGN* -139A/G was genotyped by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Amplification of fragments containing this single nucleotide polymorphism (SNP) was performed using forward primer: 5'-GTCGGAATCCAAGGCTCTC-3' and

reverse primer: 5'-CAGGAAAGCCAGGAGGTAC-3'. PCR was performed in a total of 25  $\mu$ l containing 0.1  $\mu$ M each primer, 100  $\mu$ M dNTPs, 2.5 mM MgCl<sub>2</sub>, and 0.5 unit of heat-activated DNA polymerase (IMMOLASE, Bioline USA Inc., MA) in 1 $\times$  buffer supplied with the enzyme. The thermal profile was 7 min at 95°C, followed by 30 cycles of 30 sec at 95°C, 20 sec at 58°C, and 1 min at 72°C. The 574-bp PCR products were incubated with *SpeI* restriction enzyme. The product, which contained the -139A allele, was cut into 318-bp and 256-bp fragments, and determined by electrophoresis in 2% agarose gel.

For *DC-SIGN* -336A/G genotyping, we used an allelic discrimination (AD) assay by 7500 real-time PCR with SDS analysis software (Applied Biosystems, CA). Two primers (forward primer: 5'-TGTGTTACACCCCTCCACTAG-3'; reverse primer: 5'-GGACAGTGCTTCCAGGAAG-3') were used to amplify 68-bp products containing the *DC-366A/G* SNP site, which was detected by two probes labeled with different fluorescent dyes: 5'-VIC-TACCTGCCTACCCTTG-MGB-3' to detect the "A" allele and 5'-FAM-CTGCCACCCCTTG-MGB to detect the "G" allele. Real-time PCR was performed in a 10- $\mu$ l reaction mixture containing 5  $\mu$ l of 2 $\times$  TaqMan universal master mix, 1 $\times$  primers and probes mix, and 10 ng of DNA sample. Thermocycling consisted of 10 min at 95°C, followed by 40 cycles of 15 sec at 92°C and 1 min at 60°C.

#### The 69-bp repeat number in Exon 4

The 69-bp repeat number was determined by the length of the PCR products. Primers and the thermal profile for *DC-SIGNR* 69-bp repeat number genotyping was performed as previously described.<sup>13</sup> For *DC-SIGN* 69-bp repeat number genotyping, forward primer: 5'-CCTTGGCTTCACAAATGATGTCC-3' and reverse primer: 5'-CACCCACTGCAGCCTTCAGCTG-3' were used in the PCR condition as described above. The thermal profile was 7 min at 95°C, followed by 40 cycles of 15 sec at 95°C, 15 sec at 64°C, and 1 min at 72°C. The PCR products were analyzed by electrophoresis in 2% agarose gel.

#### *DC-SIGNR* Exon 5 (rs2277998)

A/G SNP of rs2277998 was genotyped by PCR-RFLP as previously described.<sup>18</sup>

#### Data management and sample analysis

We conducted this study in a blinded manner between field investigators and laboratory investigators. The proportions of individuals possessing a certain allele/genotype among different groups were compared by a chi-square test or Fisher's exact test. Odds ratio (OR) and 95% confidence interval (95% CI) were used to measure the strength of the genetic influence associated with susceptibility to HIV infection. All statistical analyses were carried out using Epi Info version 3.01 (US CDC). *DC-SIGNR* haplotypes were constructed and estimated for their frequencies by the expectation-maximization algorithm (Arlequin version 3.01, Genetica and Biometry Laboratory, Geneva, Switzerland).

## RESULTS

#### Genotyping of polymorphisms in *DC-SIGN* and *DC-SIGNR*

We genotyped the five polymorphisms (three in *DC-SIGN* and two in *DC-SIGNR*) in 102 HIV-seronegative individuals, 305 HIV-seropositive individuals, and 290 blood donors (Table 2). We then compared the proportions of individuals possessing a specific genotype between HIV-seronegative and HIV-seropositive individuals (Table 3).

As for the two SNP sites in the *DC-SIGN* promoter, we did not find any significant differences in the proportion of individuals possessing the G allele (genotype G/G and A/G). The *DC-SIGN* 69-bp repeat number was highly conserved; the genotype 7/7 repeat was found almost exclusively at a frequency of 0.99. In contrast, we found some significant differences in genetic polymorphisms in *DC-SIGNR* associated with HIV infection.

TABLE 1. CHARACTERISTICS OF HIV-SEROPOSITIVE INDIVIDUALS

	Male		Female	
	With HIV -ve spouse (n = 43)	With HIV +ve spouse (n = 118)	With HIV -ve spouse (n = 27 <sup>a</sup> )	With HIV +ve spouse (n = 118)
Median age; years (IQR) <sup>b</sup>	34 (31, 38)	33 (30, 37)	31 (28, 35)	30 (27, 35)
Median viral load, <sup>c</sup> log <sub>10</sub> copies/ml (IQR)	5.257 (4.915, 5.757)	5.305 (4.773, 5.756)	4.939 (4.358, 5.579)	4.993 (4.214, 5.477)
Median CD4 count, <sup>c</sup> cells/mm <sup>3</sup> (IQR)	28 (13, 72)	38 (11, 246)	321 (157, 524)	277 (148, 427)
HIV-1-related symptoms, <sup>c</sup> % (n)	79.1 (34)	59.5 (69)	33.3 (9)	27.4 (32)
Diagnosis of AIDS, <sup>c</sup> % (n)	65.1 (28)	38.8 (45)	11.1 (3)	12.8 (15)

<sup>a</sup>This includes a female who was counted as a concordant couple with her previous HIV +ve husband.

<sup>b</sup>IQR, interquartile-range.

<sup>c</sup>Data not available on two concordant couples.

TABLE 2. DISTRIBUTION OF GENOTYPES [No. (%)] OF POLYMORPHISMS IN DC-SIGN AND DC-SIGNR AMONG HIV-SERONEGATIVE AND HIV-SEROPOSITIVE INDIVIDUALS

	HIV-seronegative				HIV-seropositive				Blood donor			
	Male (n = 28)		Female (n = 74)		Total (n = 102)		Male (n = 161)		Female (n = 144)		Total (n = 305)	
<b>DC-SIGN</b>												
Promoter region												
-139 (rs2287886)	A/A 16 (57.14)	A/A 31 (41.89)	47 (46.08)	64 (39.75)	74 (51.39)	138 (45.25)	146 (50.34)					
	A/G 9 (32.14)	A/G 35 (47.30)	44 (43.14)	86 (53.42)	56 (38.89)	142 (46.56)	120 (41.38)					
	G/G 3 (10.71)	G/G 8 (10.81)	11 (10.78)	11 (6.83)	14 (9.72)	25 (8.20)	24 (8.28)					
-336 (rs4804803)	A/A 22 (78.57)	A/A 59 (79.73)	81 (79.41)	119 (73.91)	121 (84.03)	240 (78.69)	237 (81.72)					
	A/G 6 (21.43)	A/G 13 (17.57)	19 (18.63)	40 (24.84)	21 (14.58)	61 (20.00)	51 (17.59)					
	G/G 0 (0.00)	G/G 2 (2.70)	2 (1.96)	2 (1.24)	2 (1.39)	4 (1.31)	2 (0.69)					
Exon 4	7/5 0 (0.00)	7/5 0 (0.00)	0 (0.00)	1 (0.62)	0 (0.00)	1 (0.33)	0 (0.00)					
69-bp repeat numbers	7/7 28 (100.00)	7/7 73 (98.65)	101 (99.02)	160 (99.38)	144 (100.00)	304 (99.67)	288 (99.31)					
	8/7 0 (0.00)	8/7 1 (1.35)	1 (0.98)	0 (0.00)	0 (0.00)	0 (0.00)	2 (0.69)					
<b>DC-SIGNR</b>												
Exon 5 (rs2277998)	G/G 19 (67.86)	G/G 46 (62.16)	65 (63.73)	111 (68.94)	115 (79.86)	226 (74.10)	215 (74.14)					
	A/G 9 (32.14)	A/G 28 (37.84)	37 (36.27)	45 (27.95)	25 (17.36)	70 (22.95)	66 (22.76)					
	A/A 0 (0.00)	A/A 0 (0.00)	0 (0.00)	5 (3.11)	4 (2.78)	9 (2.95)	9 (3.10)					
Exon 4	5/5 0 (0.00)	5/5 0 (0.00)	0 (0.00)	4 (2.48)	4 (2.78)	8 (2.62)	11 (3.79)					
69-bp repeat numbers	6/5 0 (0.00)	6/5 0 (0.00)	0 (0.00)	4 (2.48)	0 (0.00)	4 (1.31)	3 (1.03)					
	6/6 0 (0.00)	6/6 0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (0.34)					
	7/5 6 (21.43)	7/5 21 (28.38)	27 (26.47)	33 (20.50)	19 (13.19)	52 (17.05)	47 (16.21)					
	7/6 3 (10.71)	7/6 6 (8.11)	9 (8.82)	12 (7.45)	8 (5.56)	20 (6.56)	23 (7.93)					
	7/7 9 (32.14)	7/7 22 (29.73)	31 (30.39)	52 (32.30)	62 (43.06)	114 (37.38)	133 (45.86)					
	8/5 0 (0.00)	8/5 0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (0.34)					
	8/7 1 (3.57)	8/7 1 (1.35)	2 (1.96)	1 (0.62)	0 (0.00)	1 (0.33)	0 (0.00)					
	9/5 3 (10.71)	9/5 7 (9.46)	10 (9.80)	8 (4.97)	4 (2.78)	12 (3.93)	8 (2.76)					
	9/6 1 (3.57)	9/6 0 (0.00)	1 (0.98)	4 (2.48)	1 (0.69)	5 (1.64)	0 (0.00)					
	9/7 5 (17.86)	9/7 14 (18.92)	19 (18.63)	39 (24.22)	40 (27.78)	79 (25.90)	56 (19.31)					
	9/9 0 (0.00)	9/9 3 (4.05)	3 (2.94)	4 (2.48)	5 (3.47)	9 (2.95)	7 (2.41)					
	10/7 0 (0.00)	10/7 0 (0.00)	0 (0.00)	0 (0.00)	1 (0.69)	1 (0.33)	0 (0.00)					

TABLE 3. COMPARISON OF PROPORTIONS [ODDS RATIO (95% CI) AND *p* VALUE] OF INDIVIDUALS POSSESSING CERTAIN GENOTYPE BETWEEN HIV-SERONEGATIVE AND HIV-SEROPOSITIVE INDIVIDUALS

Polymorphism	Genotype	Total		Male		Female	
		OR (95% CI)	<i>p</i>	OR (95% CI)	<i>p</i>	OR (95% CI)	<i>p</i>
<i>DC-SIGN</i>							
-139 (rs2287886)	G/G and A/G	1.03 (0.64, 1.66)	0.8838	2.02 (0.84, 4.91)	0.0856	0.68 (0.37, 1.25)	0.1839
-336 (rs4804803)	G/G and A/G	1.04 (0.58, 1.89)	0.8769	1.29 (0.47, 4.17)	0.6012	0.75 (0.34, 1.64)	0.4283
69-bp repeat numbers	7/7	0.33 (0.00, 26.34)	0.4389	Undefined	1.0000	0.00 (0.00, 20.04)	0.3394
<i>DC-SIGNR</i>							
Exon 5 (rs2277998)	A/A and G/G	0.61 (0.37, 1.02)	0.0445	0.95 (0.37, 2.46)	0.9088	0.41 (0.21, 0.81)	0.0049
69-bp repeat numbers	5/5	Undefined	0.2097	Undefined	1.0000	Undefined	0.3022
	6/5	Undefined	0.5760	Undefined	1.0000	—	—
	6/6	—	—	—	—	—	—
	7/5	0.57 (0.32, 1.01)	0.0373	0.95 (0.34, 3.9)	0.9105	0.38 (0.18, 0.82)	0.0061
	7/6	0.73 (0.30, 1.79)	0.4412	0.67 (0.16, 3.97)	0.4699	0.67 (0.19, 2.44)	0.5613
	7/7	1.37 (0.82, 2.28)	0.2022	1.01 (0.40, 2.60)	0.9870	1.79 (0.94, 3.40)	0.0556
	8/5	—	—	—	—	—	—
	8/7	0.16 (0.00, 3.21)	0.1562	0.17 (0.00, 13.73)	0.2750	0.00 (0.00, 20.04)	0.3394
	9/5	0.38 (0.15, 0.98)	0.0232	0.44 (0.10, 2.73)	0.2112	0.27 (0.06, 1.13)	0.0477
	9/6	1.68 (0.19, 80.39)	1.0000	0.69 (0.06, 35.12)	0.5556	Undefined	1.0000
	9/7	1.53 (0.84, 2.78)	0.1369	1.47 (0.50, 5.28)	0.4619	1.65 (0.79, 3.47)	0.1513
	9/9	1.00 (0.24, 5.88)	1.0000	Undefined	1.0000	0.85 (0.16, 5.64)	1.0000
	10/7	Undefined	1.0000	—	—	Undefined	1.0000

As for the *DC-SIGNR* 69-bp repeat number, we found a variation from 5 to 10 repeats with 13 genotypes. The most common genotype in our study population was the 7/7 repeat, followed by the 9/7 and 7/5 repeats. We found that HIV-seronegative individuals had a significantly higher frequency of possessing the heterozygous 7/5 or 9/5 repeat than HIV-seropositive individuals ( $p = 0.037$  and  $0.023$ , respectively). Interestingly, we did not find any individuals with three or four repeats, which were found occasionally in whites. Instead we found one individual with 10 repeats that had not been reported elsewhere. For the SNP in *DC-SIGNR* Exon 5 (rs2277998), the proportion of individuals possessing the A allele (genotype A/A and A/G) was significantly higher in HIV-

seronegative than that in HIV-seropositive individuals ( $p = 0.0445$ ).

We further analyzed these associations after stratifying the study population into male and female groups (Table 3). Interestingly, we found that these associations remained significant in females ( $p = 0.0061$  for the 7/5 repeat,  $p = 0.0477$  for the 9/5 repeat, and  $p = 0.0049$  for the A allele at the SNP rs2277998A) but not in males ( $p = 0.9105$  for the 7/5 repeat,  $p = 0.2112$  for the 9/5 repeat, and  $p = 0.9088$  for the A allele at the SNP rs2277998A). Moreover, we found that HIV-seropositive females tend to have the homozygous 7/7 repeat more frequently than HIV-seronegative females with a marginal level of significance ( $p = 0.0556$ ). Again, this association was not found in males.

TABLE 4. DISTRIBUTION OF DC-SIGNR HAPLOTYPE [No. (%)] AMONG HIV-SERONEGATIVE AND HIV-SEROPOSITIVE INDIVIDUALS AND BLOOD DONORS

DC-SIGNR haplotype <sup>a</sup>	HIV-seronegative			HIV-seropositive			Blood donor (n = 580)
	Male (n = 56)	Female (n = 148)	Total (n = 204)	Male (n = 322)	Female (n = 288)	Total (n = 610)	
5A	9 (16.07)	28 (18.92) <sup>b</sup>	37 (18.14)	51 (15.84)	30 (10.42) <sup>b</sup>	81 (13.28)	77 (13.28)
6A	0 (0.00)	0 (0.00)	0 (0.00)	3 (0.93)	3 (1.04)	6 (0.98)	1 (0.17)
7A	0 (0.00)	0 (0.00)	0 (0.00)	1 (0.31)	1 (0.35)	1 (0.16)	2 (0.34)
5G	0 (0.00)	0 (0.00)	0 (0.00)	2 (0.62)	1 (0.35)	3 (0.49)	5 (0.86)
6G	4 (7.14)	6 (4.05)	10 (4.90)	17 (5.28)	6 (2.08)	23 (3.77)	26 (4.48)
7G	33 (58.93)	86 (58.11)	119 (58.33)	188 (58.39)	190 (65.97)	379 (62.13)	390 (67.24)
8G	1 (1.79)	1 (0.68)	2 (0.98)	1 (0.31)	1 (0.35)	2 (0.33)	1 (0.17)
9G	9 (16.07)	27 (18.24)	36 (17.65)	59 (18.32)	55 (19.10)	114 (18.69)	78 (13.45)
10G	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	1 (0.35)	1 (0.16)	0 (0.00)

<sup>a</sup>Haplotypes were constructed from repeat number of 69-bp (Exon 4) and A/G allele at rs227799 (Exon 5).

<sup>b</sup>HIV-seronegative female versus HIV-seropositive female;  $p = 0.0133$ , OR (95% CI) = 0.50 (0.27, 0.90).